Ipsen S.A (0MH6) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Ipsen S.A €215, price €140, upside +53.7%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €73.95 – €171.28 · fair‑value band €150.67 – €482.93 · the €140.00 price screens below the €215.24 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally.
Show more
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.
Stock analysis
Ipsen S.A (0MH6) currently trades at €140.00, while our model-based Fair Value estimate is €215.24, implying the stock looks roughly 35.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €269.45 per share, and 16 of the 25 models we run sit above the €140.00 price.
Bear case: the Asset-Based group reads lowest at €26.06, and 9 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: €150.67 (bear) to €482.93 (bull), the price of €140.00 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ipsen S.A reported revenue of €2.7B in FY2020 versus €1.7B in FY2016, a compound +12.6%/yr. Reported net income was €548M in FY2020, compounding +24.8%/yr from FY2016.
Key figures
Market cap €7.6B · P/S ratio 1.94 · Dividend yield 1.0% · Net margin 20.4% · Return on equity 10.4% · Return on assets (EBIT) 10.4% · Operating margin 26.1% · Revenue (TTM) €3.9B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (medium confidence).
What moves the price
The share trades about 18% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 54%, 0MH6 screens cheaper than that median.
Fair Value models
Bear €150.67Fair Value €215.24Bull €482.93
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
18.2% (2016) → 19.1% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ipsen S.A Fair Value". https://www.fairvalue-calculator.com/stock/0MH6
Frequently asked questions
Is Ipsen S.A (0MH6) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €215.24 versus a price of €140.00, about +54% upside (undervalued).
What is the fair value of 0MH6?
Our model-based fair value for Ipsen S.A is €215.24 (as of Sep 23, 2026), built from audited fundamentals. The current price: €140.00.
What is the quality score of 0MH6?
Ipsen S.A has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ipsen S.A (0MH6)?
Our model-based price target is the fair value of €215.24 (as of Sep 23, 2026) from 25 valuation models. Cautious scenario €150.67, optimistic scenario €482.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Ipsen S.A stock forecast for 2026?
Our models put fair value at €215.24, about +54% upside versus a price of €140.00 (undervalued). Cautious scenario €150.67, optimistic scenario €482.93. The calculation is refreshed regularly with new filings.
What is the revenue of Ipsen S.A (0MH6)?
Ipsen S.A reported trailing-twelve-month revenue of about €3.9B (latest available figure, as of Sep 23, 2026).
Does Ipsen S.A pay a dividend?
Ipsen S.A currently shows a dividend yield of about 1.00% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Ipsen S.A (0MH6)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ipsen S.A it is €215.24 per share (as of Sep 23, 2026), against a price of €140.00. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Ipsen S.A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0MH6 trades below its calculated fair value: price €140.00, fair value €215.24, a gap of about +54% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0MH6?
No. The price is what the market pays today (€140.00); the fair value is what the company's own numbers justify (€215.24). For Ipsen S.A the two are €75.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ipsen S.A worth?
The market values Ipsen S.A at about €7.6B (market capitalisation, as of Sep 23, 2026). Per share that is €140.00; our models calculate a fair value of €215.24 per share.
What do the bullish and bearish scenarios say about 0MH6?
Our models span a range for Ipsen S.A: cautious scenario €150.67, base €215.24, optimistic €482.93 per share (as of Sep 23, 2026, price €140.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0MH6 from its 52-week high?
Ipsen S.A trades at €140.00, about 18% below its 52-week high of €171.28 and 25% above the low of €112.31 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €215.24 is for.
Which stocks are comparable to Ipsen S.A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ipsen S.A stock attractive at the current price?
The data as of Sep 23, 2026: price €140.00, calculated fair value €215.24 (+54%), Quality Score 71/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0MH6 calculated?
We run Ipsen S.A through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €215.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ipsen S.A currently trades 35 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ipsen S.A (0MH6)?
The closing price on Oct 2, 2026 was €140.00. Our model-based fair value is €215.24, about +54% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ipsen S.A right now?
The rarer combination: high quality (71/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€150.67). The market is more pessimistic than our downside scenario. The model range is unusually wide (€150.67 to €482.93). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Ipsen S.A
How large is the market capitalisation of Ipsen S.A (0MH6)?
The market capitalisation of Ipsen S.A is €7.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ipsen S.A (0MH6)?
The price-to-sales ratio of Ipsen S.A is 1.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Ipsen S.A (0MH6)?
The dividend yield of Ipsen S.A is 1.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ipsen S.A (0MH6)?
The net margin of Ipsen S.A is 20.4% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ipsen S.A (0MH6)?
The return on equity (ROE) of Ipsen S.A is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ipsen S.A (0MH6)?
On an EBIT basis the return on assets of Ipsen S.A is 10.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ipsen S.A (0MH6)?
The operating margin of Ipsen S.A is 26.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ipsen S.A (0MH6)?
Revenue at Ipsen S.A is growing +9.3% versus a year earlier (3y avg +10.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ipsen S.A (0MH6)?
Earnings per share at Ipsen S.A are growing −3.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
